Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (3y) (2014 - 2026)
Neurocrine Biosciences (NBIX) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.30 Bn | 39.65 Bn | 2.15 Bn | 1,036.00 |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 175.00 |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 120.00 |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 434.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -295.00 |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 1,076.00 |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 1,898.00 |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.11 Bn | 7.46 Bn | 397.90 Mn | -1,755.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,076.00 |
| Mar 31, 2026 | 1,342.00 |
| Dec 31, 2025 | 222.00 |
| Sep 30, 2025 | 912.00 |
| Jun 30, 2025 | 1,158.00 |
| Mar 31, 2025 | 1,156.00 |
| Dec 31, 2024 | 1,259.00 |
| Sep 30, 2024 | 740.00 |
| Jun 30, 2024 | 1,072.00 |
| Mar 31, 2024 | 906.00 |
| Dec 31, 2023 | -91.00 |
| Sep 30, 2023 | -558.00 |
| Jun 30, 2023 | -2,379.00 |
| Mar 31, 2023 | -1,284.00 |
| Dec 31, 2022 | 382.00 |
| Sep 30, 2022 | 238.00 |
| Jun 30, 2022 | 265.00 |
| Mar 31, 2022 | 696.00 |
| Dec 31, 2021 | 149.00 |
| Sep 30, 2021 | 573.00 |